Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LncRNA marker in detection or evaluation of immune function of lung cancer

An immune function and marker technology, which can be used in the determination/inspection of microorganisms, medical preparations containing active ingredients, and drug combinations.

Pending Publication Date: 2019-09-06
JIANGSU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the application of LncRNA RUNXOR in the analysis of lung cancer immune function.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LncRNA marker in detection or evaluation of immune function of lung cancer
  • Application of LncRNA marker in detection or evaluation of immune function of lung cancer
  • Application of LncRNA marker in detection or evaluation of immune function of lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] (1) Collection and processing of samples

[0024] The peripheral blood samples of 100 lung cancer patients (53 cases of lung adenocarcinoma, 24 cases of squamous cell carcinoma, and 23 cases of small cell lung cancer) were collected as the experimental group, and 100 healthy peripheral blood samples were collected as the control group. In addition, peripheral blood samples were collected from 40 patients with lung cancer before and after surgical treatment, and these samples met the following criteria: (1) the patient was diagnosed with lung cancer for the first time and received surgical treatment for the first time; (2) the postoperative sample was 7 days after surgery collection. All above-mentioned sample providers gave informed consent, and the acquisition of samples was approved by the organizational ethics committee.

[0025] 2 ml K 2 Peripheral venous blood collected in EDTA anticoagulant tubes was centrifuged at 18°C ​​and 2000 rpm / min for 5 minutes to separa...

Embodiment 2

[0030] Example 2: Detection of Arg1 expression level in MDSCs, Th1 cells, CTL cell ratio and MDSCs

[0031] (1) The peripheral blood phenotype in the experimental group and the control group is CD33 + CD11b + CD14 - HLA-DR - The proportion of MDSCs.

[0032] According to 1×10 6 Cells / 100μL Add PBS to resuspend the cell pellet, add PE-anti-human-CD14, PE / CY5-anti-human-CD11b, APC-anti-human-HLA-DR and FITC-anti-human-CD33 antibodies or corresponding 0.25 μg of each isotype antibody. After mixing for 30 minutes at 4°C in the dark, the cells were washed with PBS and resuspended in 200 μL of PBS, and the proportion of MDSCs in peripheral blood was detected by flow cytometry (FCM).

[0033] image 3 It is a comparison chart of MDSCs in the peripheral blood samples of different types of lung cancer patients in the experimental group, the control group, and the experimental group; image 3 As shown, the expression of MDSCs in the experimental group was significantly higher t...

Embodiment 3

[0039] Example 3: Correlation analysis between the expression level of LncRNA RUNXOR in peripheral blood and the proportion of MDSCs, Th1 cells, CTL cells and the expression level of Arg1 in MDSCs

[0040] GraphPad Prism 5.0 software was used for statistical processing, the data were normally distributed, and Student's t-test was used. Correlation analysis uses Spearman's correlation coefficient analysis. P Figure 6 is the correlation analysis chart of the expression level of LncRNA RUNXOR in the experimental group, the proportion of MDSCs and the level of Arg1; Figure 7 is the correlation analysis graph between the expression level of LncRNA RUNXOR and the ratio of Th1 / CTL in the experimental group; Figure 6 , 7 As shown, through correlation analysis, it was found that the expression level of LncRNA RUNXOR in the peripheral blood of patients with lung cancer was significantly positively correlated with the proportion of MDSCs and the expression of Arg1, the main effector ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of application of molecular biology, and in particular, relates to an application of an LncRNA marker in detection or evaluation of immune function of lung cancer. LncRNA RUNXOR is found out to have obvious expression difference in blood of patients with lung cancer for the first time. Compared with a control group of normal people, an experimental group of patients with lung cancer has high-expression LncRNA molecular marker RUNXOR, and has the expression level of LncRNA RUNXOR after operation obviously reduced; with the expression of RUNX1, the differentiation and immunosuppressive function of MDSCs are regulated. Based on the finding, LncRNA RUNXOR can be used as a molecular marker for regulating the immune function of lung cancer or a target applied in clinical diagnosis or targeted treatment of lung cancer. Through detection, the LncRNA RUNXOR provided by the method can be applied in products for detection / evaluation of lung cancer immune function, is advantageous to further elucidating the mechanism of occurrence and development of lung cancer, and has important guiding significance for treatment of lung cancer.

Description

technical field [0001] The invention relates to the field of molecular biology applications, in particular to the application of a LncRNA marker in the detection or evaluation of lung cancer immune function. Background technique [0002] The morbidity and mortality of lung cancer rank first among malignant tumors in my country. At present, there are very few biomarkers for early diagnosis, immune function monitoring, and prognosis of lung cancer patients. The 5-year survival rate of patients with advanced lung cancer under traditional treatment is less than 5%. Exploring effective biomarkers for lung cancer is important for improving the treatment effect of lung cancer patients. significance. [0003] Existing studies have found that LncRNA RUNXOR can regulate the expression of RUNX1 at the epigenetic level. In acute myeloid leukemia cells, lncRNA RUNXOR directly binds to the promoter and enhancer of RUNX1 through its 3' end and participates in chromatin remodeling. In ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886A61K45/00A61P35/00A61P37/04
CPCC12Q1/6886A61K45/00A61P35/00A61P37/04C12Q2600/158C12Q2600/178
Inventor 李敏
Owner JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com